Oncolytic viruses for targeted attack on cancer stem cells generated
Scientists at the Paul-Ehrlich-Institut (PEI) have successfully created oncolytic viruses which effectively target CD133-positive cancer stem cells to infect and kill them. In animal experiments, multiple tumour foci could be completely eradicated. Cancer Research reports on the results of this research in its online edition of 4th January (Friday afternoon).
Tumours do not consist of homogenous cell populations but contain cancer stem cells which respond poorly to chemotherapy and radiotherapy and are considered to be responsible for metastatic tumours. Scientists have therefore stepped up their efforts to find ways of identifying and eliminating these "tumour-initiating cells".
The cell surface protein CD133 is currently discussed as a characteristic marker for such cancer stem cells. The PEI President’s Research Group "Molecular Biotechnology and Gene therapy" led by Professor Christian Buchholz has modified an attenuated and thus innocuous measles virus for the targeted attack on cancer stem cells. The modified virus requires the surface protein CD133 as receptor for penetration into the cell. The scientists were able to prove that the modified virus infects only CD133-positive tumor cells even when these are cultivated in close contact with CD133-negative cells.
In collaboration with Heidelberg University and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the Paul-Ehrlich-Institut’s scientists tested the anti-tumoural effect of their targeted virus using mouse models reflecting glioma, colon carcinoma, and liver cancer. The modified virus showed pronounced anti-tumoural activity in all animal models tested – the tumour growth was substantially reduced or even entirely suppressed. The scientists compared the effectiveness of their modified oncolytic measles virus with that of an oncolytic measles virus currently investigated in clinical trials which does not show any specificity for subtypes of tumour cells. "We were surprised that the CD133-specific virus showed an anti-tumoural activity which was at least as good as that of the standard virus. In the liver cancer model, the anti-tumoural activity was clearly superior and led to complete tumour remission", said Professor Buchholz. In further studies, the research team aims at elucidating why their viruses turned out to be more effective in fighting tumours than conventional oncolytic viruses which are supposed to attack all tumour cell subtypes.
Is it really only cancer cells that are attacked by the CD133-specific virus? In fact, not only cancer stem cells bear the surface marker CD133 but also haematopoietic stem cells. Yet, haematopoietic stem cells were not attacked by the oncolytic measles virus. This is due to the innate immunity of these cells, which protects them from an attack by measles virus. Many tumour cell types exhibit a defect in innate immunity allowing the virus to replicate unimpaired.
One advantage of the use of oncolytic viruses in cancer therapy is their enhancer mechanism. Infected tumor cells produce progeny virus particles which are released upon cell lysis and are able to detect further tumour cells.
Dr. Susanne Stöcker | idw
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.
Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...
Development and implementation of an advanced automobile parking navigation platform for parking services
To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...
- Siemens delivers electric propulsion system and charging stations with lithium-ion batteries charged from hydro power
- Ferry only uses 150 kilowatt hours (kWh) per route and reduces cost of fuel by 60 percent
- Milestone on the road to operating emission-free ferries
The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...
On Tuesday, 19 May 2015 the research icebreaker Polarstern will leave its home port in Bremerhaven, setting a course for the Arctic. Led by Dr Ilka Peeken from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) a team of 53 researchers from 11 countries will investigate the effects of climate change in the Arctic, from the surface ice floes down to the seafloor.
RV Polarstern will enter the sea-ice zone north of Spitsbergen. Covering two shallow regions on their way to deeper waters, the scientists on board will focus...
Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials.
To make the nanosponge-hydrogel, the team mixed nanosponges, which are nanoparticles that absorb dangerous toxins produced by MRSA, E. coli and other...